BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11168064)

  • 1. In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci.
    Auckenthaler R; Courvalin P; Féger C; Roche G;
    Clin Microbiol Infect; 2000 Nov; 6(11):608-12. PubMed ID: 11168064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin.
    von Eiff C; Reinert RR; Kresken M; Brauers J; Hafner D; Peters G
    J Clin Microbiol; 2000 Aug; 38(8):2819-23. PubMed ID: 10921933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of telithromycin and quinupristin/dalfopristin against methicillin-resistant coagulase-negative staphylococci with defined resistance genotypes.
    Novotná G; Spízek J; Janata J
    Folia Microbiol (Praha); 2007; 52(6):593-9. PubMed ID: 18450221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro bactericidal activity of daptomycin against staphylococci.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 2002 Mar; 49(3):467-70. PubMed ID: 11864946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.
    Allen GP; Cha R; Rybak MJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2606-12. PubMed ID: 12121940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.
    Dowzicky M; Nadler HL; Feger C; Talbot G; Bompart F; Pease M
    Am J Med; 1998 May; 104(5A):34S-42S. PubMed ID: 9684656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci.
    John MA; Pletch C; Hussain Z
    J Antimicrob Chemother; 2002 Dec; 50(6):933-8. PubMed ID: 12461014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
    Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
    Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of inducible clindamycin resistance among Staphylococcal isolates from different clinical specimens in western India.
    Pal N; Sharma B; Sharma R; Vyas L
    J Postgrad Med; 2010; 56(3):182-5. PubMed ID: 20739762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
    Finch RG
    Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
    Harper T; Miller D; Flynn HW
    Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
    Tünger A; Aydemir S; Uluer S; Cilli F
    Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2000 May; 44(5):1168-73. PubMed ID: 10770747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
    Entenza JM; Drugeon H; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.